VectorY presents at ASGCT 2021 about advances and challenges of vectorized antibodies for the treatment of neuromuscular diseases.

Dr. Pavlina Konstantinova, CSO and co-founder of VectorY, presented as an invited speaker in the virtual American Society of Gene and Cell Therapy (ASGCT) 2021 meeting. The title of the presentation “Shifting the paradigm of gene therapy for neuromuscular diseases” provided a broad overview about the field of vectorized antibodies, the advantages of developing vectorized antibodies for neuromuscular diseases and finalized with VectorY’s plans to address translational challenges in new ways for pre-clinical testing and patient personalization.

Attendees of the meeting can still watch the presentation on demand for 30 days on the ASGCT website.